Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer

Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmieri, Carlo, Macpherson, Iain RJ, Yan, Kelvin, Ades, Felipe, Riddle, Pippa, Ahmed, Riz, Owadally, Waheeda, Stanley, Barbara, Shah, Deep, Gojis, Ondrej, Januszewski, Adam, Lewanski, Conrad, Asher, Rebecca, Lythgoe, Daniel, de Azambuja, Evandro, Beresford, Mark, Howell, Sacha J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914352/
https://www.ncbi.nlm.nih.gov/pubmed/26334099
http://dx.doi.org/10.18632/oncotarget.4801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914352/
https://www.ncbi.nlm.nih.gov/pubmed/26334099
http://dx.doi.org/10.18632/oncotarget.4801

Ejemplares similares